Carazol0.06 mg/metered spray

Carazol is a sulfated polysaccharide derived from red seaweed, formulated as a nasal spray that acts as a physical barrier on the nasal mucosa. It is used as an adjunct treatment for the common cold, helping to trap virus particles (including rhinovirus, coronavirus, and influenza virus) before they can attach to and infect nasal epithelial cells.

• Common cold symptom relief (established use): Reduces the duration and severity of common cold symptoms when started within the first 1–2 days of symptom onset.
• Adjunct/preventive use (evidence-based, modest effect): May be used as an adjunct measure to help reduce the risk of re-infection during periods of high exposure (e.g., household contact with a cold), although evidence for this use is modest and preliminary rather than definitive.

Evidence supporting Carazol comes from a limited number of randomized controlled trials and systematic reviews reporting low-to-moderate certainty evidence. It should be regarded as a supportive/adjunct option rather than a proven cure for viral upper respiratory infections, and it does not replace other indicated antiviral or symptomatic treatments when these are medically needed.

Each dose of iota-Carrageenan nasal spray contains iota-Carrageenan, a naturally occurring sulfated polysaccharide extracted from red seaweed (Rhodophyta), as the active ingredient, formulated in an isotonic aqueous nasal spray base with standard pharmaceutical excipients (e.g., sodium chloride and stabilizing/preservative agents) to maintain nasal-compatible pH and osmolarity.

Carazol is a high-molecular-weight sulfated polysaccharide obtained from red seaweed. Unlike conventional antiviral drugs, it works through a physical/mechanical mode of action rather than a pharmacological one: on contact with the nasal mucosa it forms a thin protective gel layer that binds and traps airborne virus particles, limiting their ability to attach to and infect nasal epithelial cells. It is marketed as a nasal spray for symptomatic relief and adjunct management of the common cold.

Nasal barrier agent / natural antiviral adjunct used in the symptomatic management of the common cold (non-antibiotic, non-systemic). Carazol is not classified as a conventional systemic pharmacological agent.

Mechanism of Action

iota-Carrageenan works through a non-pharmacological, physical barrier mechanism. When sprayed intranasally, it forms a viscous, gel-like film across the nasal mucosa. This film physically traps and binds respiratory virus particles (such as rhinovirus, coronavirus, and influenza virus) that come into contact with it, preventing them from attaching to and entering nasal epithelial cells. By interrupting the earliest step of viral infection — attachment and cell entry — iota-Carrageenan may reduce viral load in nasal secretions and shorten the duration of cold symptoms.

Pharmacokinetics

iota-Carrageenan is not systemically absorbed to a clinically significant extent when used intranasally as directed. Its action is local/topical; it is cleared through normal mucociliary clearance and is not metabolized in the way a conventional systemic drug would be.

Carazol is for intranasal (nasal) use only. Shake the bottle gently before use and prime the pump before first use as directed on the package leaflet. Tilt the head slightly forward, insert the nozzle into one nostril, and spray while breathing in gently; repeat in the other nostril. Avoid spraying Carazol into the eyes or mouth. Wipe the nozzle clean after use. Do not use Carazol for longer than the labeled duration without consulting a physician.

Because Carazol acts locally on the nasal mucosa with minimal systemic absorption, no clinically significant systemic drug interactions have been established. If Carazol is used together with other intranasal products (e.g., decongestant or corticosteroid nasal sprays), space the doses a few minutes apart so that one product does not physically wash away the protective film formed by Carazol, which could reduce its barrier effect.

• Mild, transient nasal irritation or stinging after applying Carazol
• Sneezing immediately after application
• Nasal dryness

These effects are generally uncommon, mild, and self-limiting. Serious adverse effects have not been established with typical use of Carazol.

Because Carazol is applied topically to the nasal mucosa with minimal systemic absorption, it is generally considered low risk during pregnancy and breastfeeding when used as directed. However, dedicated controlled studies of Carazol in pregnant or lactating women are limited. Carazol should therefore be used during pregnancy and lactation only if clearly needed, where the potential benefit justifies any potential risk, and a physician should be consulted before use.

Carazol is intended for external/topical intranasal use only and should not be swallowed or applied to other mucosal surfaces unless specifically directed. It is a supportive/adjunct measure for common cold symptoms and is not a substitute for other indicated antiviral, antibiotic, or symptomatic treatments when these are medically necessary — Carazol is not an antibiotic and has no activity against bacterial infections. If nasal irritation persists or worsens, or if cold symptoms do not improve or worsen after several days of using Carazol, discontinue and consult a physician. Keep the spray nozzle clean between uses to avoid contamination.

Significant overdose with Carazol is unlikely given its topical route of administration and lack of meaningful systemic absorption. Excessive or off-label use (e.g., very frequent dosing) may increase the likelihood of local nasal irritation. In case of accidental ingestion of a large amount of Carazol, or if a child accidentally ingests the product, seek immediate medical attention or contact a poison control center; do not attempt unsupervised home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep the cap tightly closed when not in use. Keep out of reach of children.

Pediatric Use

Use of Carazol in young children should follow the specific product's approved age range (commonly from around 2 years of age, depending on the formulation). Safety and efficacy of Carazol in infants and very young children have not been well established, so a physician should be consulted before use in this group.

Elderly

No dose adjustment of Carazol is generally required in elderly patients, as it acts locally with minimal systemic absorption.

Renal/Hepatic Impairment

No dose adjustment of Carazol is expected to be necessary given its topical, non-systemic mode of action; however, patients with significant hepatic or renal impairment should consult a physician before use, as dedicated studies are limited.

Carazol is typically used for up to 7 days per episode of cold symptoms, or as directed on the product labeling. If symptoms have not improved or have worsened after this period of using Carazol, a physician should be consulted rather than continuing use indefinitely.

Natural sulfated polysaccharide; topical nasal barrier agent. iota-Carrageenan is used as an adjunct in the symptomatic management of the common cold rather than as a conventional systemic pharmacological class of drug.

iota-Carrageenan forms a protective gel film over the nasal mucosa that physically traps respiratory virus particles, preventing their attachment to and entry into nasal epithelial cells, thereby limiting viral replication and reducing the severity and duration of cold symptoms.

Carazol nasal spray is used in children according to specific product labeling, generally from around 2 years of age onward, at a lower dosing frequency than in adults (see Dosage and Administration). Safety and efficacy of Carazol in infants and children below the labeled minimum age have not been established, so it should not be used in this group without specific medical advice.